HC Wainwright reiterated their buy rating on shares of Precision BioSciences (NASDAQ:DTIL – Free Report) in a research note issued to investors on Friday,Benzinga reports. HC Wainwright currently has ...

BMO Capital Markets upgraded shares of Precision BioSciences (NASDAQ:DTIL – Free Report) from a market perform rating to an outperform rating in a report released on Friday, Marketbeat Ratings reports ...

NDAQ:CRBU) Caribou Biosciences Initiates the CB-010 GALLOP Phase 1 Trial in Lupus and Provides Outlook for Multiple Clinical Datasets in 2025 ...

Spatial transcriptomics was named the method of the year in 2020 (Nature 2021). Spatial transcriptomics has rapidly emerged ...

Precision BioSciences gains momentum as iECURE reports positive ECUR-506 data, and analysts forecast significant HBV ...

Fintel reports that on January 10, 2025, BMO Capital upgraded their outlook for Precision BioSciences (NasdaqCM:DTIL) from ...

Is it just market speculation, or is there something more significant unfolding behind the scenes? At the core of Precision BioSciences’ sudden stock surge is the company’s gene-editing technology, ...

Precision BioSciences (DTIL) stock saw a 31% premarket surge after positive results from its gene therapy trial for treating ...

JonesTrading analyst Soumit Roy maintained a Buy rating on Precision BioSciences (DTIL – Research Report) today and set a price target of ...

Character Biosciences Announces Collaboration with Bausch + Lomb to Transform Ophthalmology with Precision Medicine ...

BMO Capital upgraded Precision BioSciences (DTIL) to Outperform from Market Perform with an unchanged price target of $34 alter iECURE ...